Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 19/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647049 | 1.00 | GCGR (0.70) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL2647853 | 0.89 | GCGR (0.76) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL2647852 | 0.89 | GCGR (0.76) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL2647428 | 0.87 | GCGR (0.72) | GCGR | |
| SCHEMBL2647431 | 0.87 | GCGR (0.72) | GCGR | |
| SCHEMBL2647176 | 0.86 | GCGR (0.75) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL2647174 | 0.86 | GCGR (0.75) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL18947919 | 0.86 | GCGR (0.75) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL2662953 | 0.85 | GCGR (0.73) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL2648418 | 0.85 | GCGR (0.73) | GCGRESR1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |